share_log

HC Wainwright & Co. Reiterates Neutral on RAPT Therapeutics

Benzinga ·  Apr 10 18:19

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:RAPT) with a Neutral.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment